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Background: Obesity is associated with an increased risk of high-grade prostate cancer (PCa). The effect of body mass index (BMI) as a
predictor of progression in men with low-risk PCa has been only poorly assessed.
In this study, we evaluated the association of BMI with progression in patients with low-risk PCa who met the inclusion criteria for the
active surveillance (AS) protocol.
Methods: We assessed 311 patients who underwent radical prostatectomy and were eligible for AS according to the following criteria:
clinical stage T2a or less, prostate-speciﬁc antigen levelo10 ng/ml, 2 or fewer cores involved with cancer, Gleason score r6 grade, and
prostate-speciﬁc antigen densityo0.2 ng/ml/cc. Reclassiﬁcation was deﬁned as upstaged (pathological stage4pT2) and upgraded (Gleason
score Z7; primary Gleason pattern 4) disease. Seminal vesicle invasion, positive lymph nodes, and tumor volumeZ0.5 ml were also
recorded.
Results: We found that high BMI was signiﬁcantly associated with upgrading, upstaging, and seminal vesicle invasion, whereas it was
not associated with positive lymph nodes or large tumor volume. At multivariate analysis, 1 unit increase of BMI signiﬁcantly increased the
risk of upgrading, upstaging, seminal vesicle invasion, and any outcome by 21%, 23%, 27%, and 20%, respectively. The differences
between areas under the receiver operating characteristics curves comparing models with and without BMI were statistically signiﬁcant for
upgrading (P ¼ 0.0002), upstaging (P ¼ 0.0007), and any outcome (P ¼ 0.0001).
Conclusions: BMI should be a selection criterion for inclusion of patients with low-risk PCa in AS programs. Our results support the
idea that obesity is associated with worse prognosis and suggest that a close AS program is an appropriate treatment option for obese
subjects. r 2015 Elsevier Inc. All rights reserved.
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Widespread use of prostate-speciﬁc antigen (PSA) screen-
ing increased the number of tumors diagnosed at early
stages, but it also led to overdiagnosis and overtreatment of
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prostate cancer (PCa) [1]. Active surveillance (AS) recently
became an accepted alternative for patients with low-risk PCa–
related mortality, allowing for delayed curative intervention if
there is reclassiﬁcation of cancer risk or evidence of disease
progression [2]. However, risk factors for reclassiﬁcation and
progression are not adequately characterized. Obesity and
overweight pose a major risk for serious diet-related chronic
diseases, including type 2 diabetes, cardiovascular disease,
hypertension and stroke, and certain forms of cancer, espe-
cially the hormonally related. In the last decade, multiple
epidemiologic studies suggested that obesity is associated with
increased risk and death from numerous cancer types includ-
ing PCa [3,4]. Several biological derangements such as
hyperinsulinemia, serum adipokine levels, elevated vascular
endothelial growth factor levels, and alterations in sex
hormone levels have negative implications for cancer pro-
gression [5]. In this study, we evaluated the effect of body
mass index (BMI) on the prediction of upgrading, upstaging,
positive lymph nodes, seminal vesicle invasion, and tumor
volume Z0.5 ml in a cohort of patients with very low-risk
PCa who met the inclusion criteria for the PRIAS protocol but
elected to undergo radical prostatectomy (RP).Table 1
Patient and tumor characteristics of the study population
n (%)
Agea 62.71 (5.61)
PSA levela 5.88 (1.85)
PSA densitya 0.12 (0.04)
Clinical stage
cT1c 282 (91%)
cT2a 28 (9%)
Pathological stage
pT2a 37 (12%)
pT2b 10 (3%)
pT2c 199 (64%)
pT3a 53 (17%)
pT3b 11 (4%)
Gleason score
6 172 (55%)
7 130 (42%)
3 þ 4 79 (61%)
4 þ 3 51 (39%)
Z8 8 (3%)
Positive cores
1 163 (53%)
2 147 (47%)
BMI
18–24 161 (52%)
25–29 80 (26%)
30þ 69 (22%)
aMean ( standard deviation).2. Patients and methods
We retrospectively reviewed the medical records of
2,200 patients who underwent robotic RP for PCa between
November 2008 and May 2014. None of the patients
included in the current study received neoadjuvant andro-
gen deprivation therapy or drugs that could alter the PSA
values, such as dutasteride and ﬁnasteride. Patients with no
biopsy slide or incomplete data were excluded. In total, 311
patients fulﬁlled the inclusion criteria for “Prostate Cancer
Research International: Active Surveillance” [6] deﬁned as
follows: clinical stage T2a or less, PSA levelo10 ng/ml,
2 or fewer cores involved with cancer after a biopsy scheme
of at least 12 cores, Gleason score (GS)r6 grade, and PSA
density (PSA-D) o0.2 ng/ml/cc. We compared the patho-
logical ﬁndings between specimens after RP and prostate
biopsies. RP specimens were processed and evaluated
according to the Stanford protocol [7] by a single, experi-
enced, genitourinary pathologist (G.R.) blinded to index
tests results. PCa was identiﬁed and graded according to the
deﬁnitions of the 2005 consensus conference of the Interna-
tional Society of Urological Pathology [8].
2.1. Statistical analysis
BMI was classiﬁed according to the 3 standard catego-
ries: 18-24 (normal weight), 25-29 (overweight), andZ30
(obese). Classiﬁcation of outcomes were upstaging (patho-
logical stage4pT2) upgrading (GS Z 7), seminal vesicle
invasion (yes/no), positive lymph nodes (yes/no), and large
tumor volume (Z0.5 ml).Informative parameters for the distribution of contin-
uous variables (age, BMI, PSA level, and PSA-D) were
calculated, and their distributions were tested for normal-
ity by the Kolmogorov-Smirnov test. As age and BMI
were not normally distributed, nonparametric tests were
applied for analyses on these variables. Univariate
analyses were performed to evaluate the association of
patient and tumor characteristics with upgrading, upstag-
ing, positive lymph nodes, seminal vesicle invasion, and
large tumor volume. The association for continuous
variables was assessed by t test (PSA level and PSA-D)
or nonparametric 2-sample Wilcoxon test (age and BMI);
the association for categorical variables was assessed
using the chi-square test or the Fisher exact test, as
appropriate. Variation of BMI according to each category
of GS was also evaluated, considering the GS ¼ 4 þ 3
and the GS ¼ 3 þ 4 categories separately, with the
nonparametric Wilcoxon test. Linear regression was
performed to test for a linear trend between log-
transformed BMI values and GS categories.
Multivariate unconditional logistic regression models
were performed to assess the independent contribution of
patient and tumor characteristics in the prediction of
upgrading, upstaging, positive lymph nodes, seminal
vesicle invasion, large tumor volume, and any of the
previous outcomes; odds ratio and 95% CIs were
Table 2
Univariate analysis for the association between patient and tumor
characteristics with (a) upgrading, (b) upstaging, (c) positive lymph nodes,
(d) seminal vesicle invasion, (e) tumor volume, and (f) any of the previous
outcomes
“Yes”, n (%) “No”, n (%) P valuea
(a) Upgrading
Ageb 63.07 (5.56) 62.41 (5.65) 0.25
PSA levelb 5.94 (1.78) 5.83 (1.90) 0.60
PSA densityb 0.13 (0.04) 0.12 (0.04) 0.30
Positive cores 0.30
1 68 (42%) 95 (58%)
2 70 (48%) 77 (52%)
Clinical stage 0.17
cT1c 129 (46%) 153 (54%)
cT2a 9 (32%) 19 (68%)
BMI o0.0001
18–24 46 (29%) 115 (71%)
25–29 47 (59%) 33 (41%)
30þ 45 (65%) 24 (35%)
(b) Upstaging
Ageb 62.81 (5.19) 62.68 (5.73) 0.93
PSA levelb 5.99 (1.86) 5.85 (1.84) 0.59
PSA densityb 0.12 (0.04) 0.12 (0.04) 0.94
Positive cores 0.11
1 28 (17%) 135 (83%)
2 36 (24%) 111 (76%)
Clinical stage 0.91
cT1c 58 (21%) 224 (79%)
cT2a 6 (21%) 22 (79%)
BMI o0.0001
18–24 16 (10%) 145 (90%)
25–29 20 (25%) 60 (75%)
30þ 28 (41%) 41 (59%)
(c) Positive lymph nodes
Ageb 61.70 (8.41) 62.74 (5.51) 0.93
PSA levelb 5.86 (2.05) 5.88 (1.84) 0.97
PSA densityb 0.13 (0.06) 0.12 (0.04) 0.88
Positive cores 0.75
1 6 (4%) 157 (96%)
2 4 (3%) 143 (97%)
Clinical stage 0.23
cT1c 8 (3%) 274 (97%)
cT2a 2 (7%) 26 (93%)
BMI 1.00
18–24 6 (4%) 155 (96%)
25–29 2 (3%) 78 (97%)
30þ 2 (3%) 67 (97%)
(d) Seminal vesicle invasion
Ageb 65.00 (3.41) 62.62 (5.66) 0.18
PSA levelb 5.89 (1.58) 5.88 (1.86) 0.99
PSA densityb 0.11 (0.04) 0.12 (0.04) 0.27
Positive cores 0.23
1 8 (5%) 155 (95%)
2 3 (2%) 144 (98%)
Clinical stage 0.01
cT1c 7 (2%) 275 (98%)
cT2a 4 (14%) 24 (86%)
BMI 0.01
18–24 2 (1%) 159 (99%)
25–29 2 (3%) 78 (98%)
30þ 7 (10%) 62 (90%)
Table 2
Continued
(e) Tumor volume o0.5 ml, n (%) Z0.5 ml, n (%)
Ageb 64.33 (4.85) 62.61 (5.65) 0.19
PSA levelb 6.4 (2.02) 5.85 (1.83) 0.22
PSA densityb 0.14 (0.04) 0.12 (0.04) 0.14
Positive cores 0.22
1 12 (7%) 151 (93%)
2 6 (4%) 141 (96%)
Clinical stage 1.00
cT1c 17 (6%) 265 (94%)
cT2a 1 (4%) 27 (96%)
BMI 0.40
18–24 12 (7%) 149 (93%)
25–29 4 (5%) 76 (95%)
30þ 2 (3%) 67 (97%)
(f) Any outcome
Ageb 63.03 (5.56) 62.32 (5.67) 0.20
PSA levelb 5.94 (1.86) 5.81 (1.83) 0.55
PSA densityb 0.12 (0.04) 0.12 (0.04) 0.51
Positive cores 0.32
1 84 (52%) 79 (48%)
2 84 (57%) 63 (43%)
Clinical stage 0.21
cT1c 156 (55%) 123 (45%)
cT2a 12 (43%) 16 (57%)
BMI o0.0001
18–24 64 (40%) 97 (60%)
25–29 55 (69%) 25 (31%)
30þ 49 (71%) 20 (29%)
Note: signiﬁcant P values are in bold.
at Test or nonparametric 2-sample Wilcoxon test for continuous
variables, as appropriate; chi-square test or Fisher exact test for categorical
variables, as appropriate.
bMean ( standard deviation).
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drawn for models with and without inclusion of BMI, and
the corresponding areas under the curve of the 2 models
were compared with the DeLong test. Finally, a nomo-
gram was created to improve the clinical interpretation of
our model, predicting the risk of unfavorable disease,
deﬁned as occurrence of upgrading or upstaging or both.
Multivariable logistic regression was used to build the
nomogram, considering both categorical (positive core
and clinical stage) and continuous variables (PSA level
and BMI).
Statistical signiﬁcance was deﬁned as Po 0.05. Stat-
istical analysis was performed using SAS software, Version
9.2, and R software with Hmisc and Design libraries (Hmisc
and Design libraries http://cran.r-project.org/).3. Results
The mean age (standard deviation) of the study
subjects was 63 (6) years (Table 1). Most of the patients
(91%) had clinical stage cT1c tumors and 64% had
pathological stage pT2c tumors, followed by stage pT3a
Table 3
Univariate analysis for the association between BMI and each category of
GS
Gleason score n BMI mean (SD) P valuea
6 172 24.53 (3.37) Ref.
3 þ 4 79 26.51 (3.97) 0.0002
4 þ 3 51 28.24 (4.46) o0.0001
Z8 8 31.88 (5.08) 0.0005
Note: signiﬁcant P values are in bold. P value for linear trendo0.0001.
aNonparametric 2-sample Wilcoxon test comparing each GS category
with GS ¼ 6 (reference).
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among them 61% had GS ¼ 3 þ 4 and 39% had GS ¼
4 þ 3 (Table 1).
At univariate analysis, we found that high BMI was
signiﬁcantly associated with upgrading, upstaging, seminal
vesicle invasion and any outcome, which was deﬁned based
on the presence of at least 1 unit increase of BMI one
between upgrading, upstaging, positive lymph nodes, semi-
nal vesicle invasion and large tumor volume (Table 2 and
Fig. 1). BMI was not associated with positive lymph nodes
or large tumor volume (Table 2 and Fig. 1). There was also
a signiﬁcant association with seminal vesicle invasion of
clinical stage cT2a compared with stage cT1c (P ¼ 0.01).
Looking at the association between BMI and upgrading in
more detail, we found higher BMI values with increasingno yes
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Fig. 1. Box plots representing the BMI of patients (A) with or without upgrading
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upgrading, upstaging, seminal vesicle invasion, and any out-
come was conﬁrmed, as well as the association between
clinical stage cT2a with seminal vesicle invasion (Table 4).
According to the model with continuous BMI values, 1 unit
increase of BMI signiﬁcantly increased the risk of upgrading,
upstaging, seminal vesicle invasion, and any outcome by 21%,
23%, 27%, and 20%, respectively. The differences between
areas under the receiver operating characteristics curves
comparing models with and without BMI were statistically
signiﬁcant for upgrading (Fig. 2), upstaging (Fig. 3), and anyTable 4
Multivariate odds ratio (95% CI) and P value for predictors of (a) upgrading, (b)
volume, and (f) any of the above
Model without BMI P value Model with cont
(a) PSA level 1.04 (0.92–1.17) 0.58 0.98 (0.86–1.12)
Positive cores 1.28 (0.81–2.00) 0.29 1.20 (0.74–1.94)
Clinical stage 0.55 (0.24–1.27) 0.16 0.51 (0.21–1.25)
BMI 1.21 (1.14–1.30)
18–24 – –
25–29 – –
30þ – –
(b) PSA 1.04 (0.90–1.21) 0.60 0.98 (0.83–1.16)
Positive cores 1.56 (0.90–2.72) 0.12 1.51 (0.83–2.74)
Clinical stage 1.04 (0.40–2.68) 0.94 1.01 (0.36–2.85)
BMI 1.23 (1.15-1.33)
18–24 – –
25–29 – –
30þ – –
(c) PSA 0.99 (0.70–1.40) 0.93 0.99 (0.70–1.41)
Positive cores 0.72 (0.20–2.62) 0.62 0.73 (0.20–2.65)
Clinical stage 2.67 (0.54–13.31) 0.23 2.67 (0.54–13.30
BMI 0.98 (0.84-1.14)
18–24 – –
25–29 – –
30þ – –
(d) PSA 0.98 (0.69–1.39) 0.89 0.94 (0.64–1.38)
Positive cores 0.38 (0.10–1.48) 0.16 0.35 (0.08–1.44)
Clinical stage 6.95 (1.86–26.03) 0.004 7.14 (1.70–29.92
BMI 1.27 (1.11–1.46)
18–24 – –
25–29 – –
30þ – –
(e) PSA 1.18 (0.91–1.53) 0.20 1.22 (0.94–1.58)
Positive cores 0.53 (0.19–1.45) 0.22 0.57 (0.21–1.55)
Clinical stage 0.56 (0.07–4.45) 0.59 0.53 (0.07–4.21)
BMI 0.89 (0.77–1.03)
18–24 – –
25–29 – –
30þ – –
(f) PSA 1.04 (0.92–1.18) 0.53 0.99 (0.87–1.13)
Positive cores 1.26 (0.80–1.98) 0.32 1.18 (0.73–1.90)
Clinical stage 0.60 (0.27–1.31) 0.20 0.57 (0.24–1.33)
BMI 1.20 (1.12–1.28)
18–24 – –
25–29 – –
30þ – –
Note: significant odds ratios and P values are in bold.outcome (not shown) with P values for the differences of
0.0002, 0.0007, and 0.0001, respectively, whereas it was not
signiﬁcant for seminal vesicle invasion (not shown).
Fig. 4 shows a nomogram with PSA levels, positive
cores, clinical stage, and BMI, predicting the risk of
unfavorable disease. BMI seemed the predictor that
contributed most on increasing the risk of unfavorable
disease in this cohort of patients, with overweight
patients having a risk of unfavorable disease, in the
absence of other risk factors, of approximately 25%–85%
for BMI of 25–40.upstaging, (c) positive lymph nodes, (d) seminal vesicle invasion, (e) tumor
inuous BMI P value Model with 3 classes of BMI P value
0.77 0.98 (0.86–1.12) 0.79
0.46 1.16 (0.72–1.87) 0.55
0.14 0.54 (0.22–1.31) 0.17
o0.0001
1.00 (reference)
3.42 (1.93–6.05) o0.0001
4.87 (2.63–8.99) o0.0001
0.83 0.98 (0.84–1.16) 0.85
0.18 1.49 (0.83–2.67) 0.18
0.98 1.01 (0.37–2.78) 0.99
o0.0001
1.00 (reference)
2.90 (1.39–6.05) 0.004
6.20 (3.03–12.67) o0.0001
0.96 1.00 (0.70–1.41) 0.98
0.63 0.74 (0.20–2.69) 0.64
) 0.23 2.64 (0.52–13.46) 0.24
0.77
1.00 (reference)
0.75 (0.14–3.92) 0.73
0.74 (0.14–3.84) 0.72
0.75 0.92 (0.63–1.34) 0.67
0.14 0.38 (0.09–1.54) 0.17
) 0.01 6.21 (1.52–25.38) 0.01
0.001
1.00 (reference)
2.95 (0.39–22.34) 0.30
9.18 (1.78–47.26) 0.01
0.13 1.21 (0.93–1.56) 0.15
0.28 0.56 (0.20–1.55) 0.26
0.54 0.58 (0.07–4.62) 0.61
0.11
1.00 (reference)
0.64 (0.20–2.10) 0.46
0.35 (0.08–1.62) 0.18
0.89 0.99 (0.88–1.13) 0.94
0.50 1.15 (0.71–1.84) 0.57
0.19 0.61 (0.26–1.39) 0.24
o0.0001
1.00 (reference)
3.20 (1.80–5.69) o0.0001
3.80 (2.05–7.04) o0.0001
Fig. 2. ROC curves for upgrading comparing models with and without inclusion of BMI with (A) continuous BMI and (B) 3 classes of BMI. ROC, receiver
operating characteristics. (Color version of ﬁgure is available online.)
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Although, in recent years, there has been progress
toward identifying the best candidates for AS, risk factorsFig. 3. ROC curves for upstaging comparing models with and without inclusion
operating characteristics. (Color version of ﬁgure is available online.)for reclassiﬁcation and progression are not adequately
characterized. This is particularly worrisome in men with
a life expectancy of more than 10 to 15 years. Recently,
number of biopsy cores emerged as an independentof BMI with (A) continuous BMI and (B) 3 classes of BMI. ROC, receiver
Fig. 4. Nomogram with PSA level, positive cores, clinical stage (cT), and BMI predicting the risk of unfavorable disease (UD), deﬁned as occurrence of
upstaging or upgrading or both.
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able disease at RP [9], suggesting that the extent of initial
biopsy sampling could improve patient selection and
surveillance strategy planning [10]. The PRIAS study
showed that in addition to age and PSA level at diagnosis,
both PSA-D and the number of positive cores at diagnosis
(2 compared with 1) are the strongest predictors for
reclassiﬁcation biopsy or switching to deferred treatment.
It was found that the disease-speciﬁc survival rate was
100%, and it was concluded based on the short-term data
that AS is a feasible strategy to reduce overtreatment [11].
Furthermore, emerging data indicated that demographic
factors such as race or BMI may help differentiate better
candidates for surveillance [12]. Obesity is a modiﬁable risk
factor that warrants special attention. The lower testosterone
level and hemodilution resulting from the increased plasma
volume in obese men may be responsible for decreased
serum PSA levels, leading to delayed diagnosis [13].
Increasing BMI is associated with shorter time to PSA
treatment failure after RP [14] and androgen suppression
therapy or radiation therapy for clinically localized PCa
[15].
Circulating hormones (i.e., insulin, free insulinlike
growth factor-1, and testosterone), cytokines (i.e., IL-6),
and other factors such as leptin and adiponectin are altered
in obese subjects and might promote PCa progression [5].
Besides, we and others previously demonstrated that
insulinlike growth factor-binding protein, IL-6 soluble
receptor, and adipokines are biomarkers of poor prognosis
in patients with PCa [16–18]. Although the association
between obesity and PCa incidence is controversial, liter-
ature data consistently indicated that obesity is associated
with a reduced risk of low-risk, PSA-detected cancers and
an increased risk of high-grade, lethal cancers [5,19].
Moreover, most large observational series have shown that
obesity is a risk factor for adverse pathological features,
higher advanced stage, risk for biochemical recurrence after
RP, and risk of death from PCa [14,20,21].
On this basis, a key question is whether obesity is a risk
factor for PCa progression in men with PCa who are on AS.To the best of our knowledge, few studies evaluated the
ability of BMI for patient selection in AS of those with PCa
[22,23]. In a recent study, a cohort of 565 men with low-
risk PCa on initial biopsy selected for AS has been
evaluated, showing that obesity is independently associated
with a higher risk of pathological and therapeutic progres-
sion [24].
Our ﬁndings suggested that BMI is associated with an
increased risk of upgraded and upstaged disease and it was sign-
iﬁcantly higher in patients with seminal vesicle invasion, but not
in patients with positive lymph nodes and large tumor volume.
Moreover, models including BMI showed a signiﬁcant
increased ability to predict the risk of upgrading and
upstaging, although their prediction accuracy is generally
fair (areas under the curveZ0.70).
These data further support the idea that obesity is
associated with PCa aggressiveness. AS protocols in these
patients should include close surveillance scheme in order
to early identify tumors progression.
The present study had some limitations. First, our study
was performed retrospectively, and the data were analyzed
in selected patients who underwent RP rather than all
patients with biopsy-conﬁrmed PCa. Therefore, there might
have been the inherent bias of a retrospective design and a
selection bias. However, RP is necessary to conﬁrm the
pathological characteristics of insigniﬁcant PCa. Second,
we focused primarily on the pathological ﬁndings but did
not assess biochemical recurrence or PCa-speciﬁc mortality,
which might be a more important issue than the adverse
pathological characteristics.5. Conclusion
In conclusion, compared with normal or overweight men
eligible for AS, obese men are at a higher risk of upgraded
and upstaged disease. These results encourage urologists to
inform obese men eligible for AS about this risk of
reclassiﬁcation and may help improve treatment decision
making.
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